MedTrace Logo

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis

NCT07169682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2025-09-12

No results posted yet for this study

Summary

Data on the antiatherogenic effect of IL23 inhibitors are sparse. This study aimed to assess the impact of one-year treatment with an IL17 or IL23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.

This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL17 inhibitor or an IL23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).

Conditions

Interventions

DRUG

interleukin 17 inhibitor

52 weeks

DRUG

interleukin-23 inhibitor

52 weeks

DRUG

conventional systemic agent or apremilast

52 weeks

Sponsors & Collaborators

  • Andreas Syggros Hospital of Venereal and Dermatological Diseases

    collaborator OTHER

  • National and Kapodistrian University of Athens

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2024-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07169682 on ClinicalTrials.gov